VANCOUVER - Celly Nutrition Corp., a wellness and recovery supplement company, has entered into a master distribution agreement with FUSION Consulting Group to distribute its alcohol metabolism supplement, unbuzzd™, across Puerto Rico, the Caribbean, and parts of Central and South America. The announcement was made today, marking a significant expansion for the company's innovative product line.
The agreement with FUSION, a distributor known for its health-conscious food and beverage brands, will introduce unbuzzd™ to new markets through FUSION's established network. This partnership is expected to leverage FUSION's experience in growing brands within the region to increase the footprint of Celly Nu's product.
unbuzzd™, which comes in Ready-to-Mix (RTM) powder sticks and soon-to-be-launched Ready-to-Drink (RTD) 12oz cans, is designed to support the body's natural processes for metabolizing alcohol and promoting alertness. The product is currently available on Amazon (NASDAQ:AMZN) in 3-packs and 18 packs.
John Duffy, CEO of Celly Nutrition Corp. and former Vice-President of National Sales of Coca-Cola (NYSE:KO), expressed enthusiasm about the collaboration, emphasizing the functional and science-backed nature of unbuzzd™. Eduardo Santacana, CEO of FUSION Consulting Group, highlighted the product's potential to improve clarity and minimize the aftereffects of drinking.
The partnership aims to capitalize on key vacation destinations where alcohol consumption is commonplace, targeting major retail customers like Walmart (NYSE:WMT), Walgreens, CVS, and Costco (NASDAQ:COST).
Celly Nutrition has a global licensing agreement with Quantum (NASDAQ:QMCO) BioPharma Ltd., which invented unbuzzd™ and retains a 25.71% ownership of Celly Nutrition as of June 30, 2024. Quantum BioPharma also benefits from royalty payments from the sales of unbuzzd™ and holds the rights to develop similar products for pharmaceutical and medical uses.
This news release includes forward-looking statements regarding the potential benefits of the partnership and the launch of unbuzzd™ RTD cans. The company cautions that these statements are based on assumptions and that actual events may differ materially due to various risks and uncertainties.
The information in this article is based on a press release statement from Quantum BioPharma Ltd. and does not imply any endorsements of claims made. The efficacy of unbuzzd™ has not been evaluated by the U.S. Food and Drug Administration, Health Canada, or other regulatory bodies, and clinical trials have not been conducted to confirm the efficacy of the product.
In other recent news, Quantum BioPharma Ltd. has announced a partnership with Ingenu CRO Pty Ltd to conduct an observational clinical study on primary progressive multiple sclerosis (MS). The research is a precursor to a future phase 2 clinical trial of the drug candidate Lucid-21-302, also known as Lucid-MS. Furthermore, Quantum BioPharma's licensee, Celly Nutrition Corp., has signed a Master Distribution Agreement with FUSION Distribution Group to distribute its new beverage product, unbuzzd™, in Puerto Rico, the Caribbean, and parts of Central and South America.
In other developments, FSD Pharma Inc. has settled debts by issuing 650,000 Class B Subordinate Voting shares and won a court judgment against its former CEO, Dr. Raza Bokhari, who is now required to pay over CAD $2.9 million plus interest. The company also received approval to commence a Phase 1 clinical trial for its drug candidate, Lucid-21-302, for treating multiple sclerosis. Additionally, FSD Pharma has been given approval to start its METAL-2 trial in the United States, exploring treatments for acute alcohol intoxication.
Finally, both Quantum BioPharma and FSD Pharma have been involved in various partnerships and agreements, aiming to expand their market presence and develop innovative solutions in the biopharmaceutical sector. These recent developments are part of the companies' continuous efforts to address complex health issues.
InvestingPro Insights
As Quantum BioPharma Ltd. (QNTM) ventures into new markets through its subsidiary Celly Nutrition Corp., investors should consider some key financial metrics and trends. According to InvestingPro data, QNTM has a market capitalization of $8.53 million USD, reflecting its current small-cap status in the biotech sector.
InvestingPro Tips reveal that QNTM holds more cash than debt on its balance sheet, which could provide financial flexibility as it expands its unbuzzd™ product line. This strong cash position may be crucial for supporting the company's growth initiatives, including the new distribution agreement with FUSION Consulting Group.
However, it's important to note that QNTM is not currently profitable, with a negative P/E ratio of -0.98 over the last twelve months as of Q2 2024. Despite this, analysts predict the company will be profitable this year, which aligns with the potential revenue growth from the expanded distribution of unbuzzd™.
The stock has shown significant volatility, with a 15% return over the last week but a substantial decline of 94.1% over the past year. This volatility underscores the speculative nature of investing in small-cap biotech companies like QNTM.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for QNTM, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.